<DOC>
	<DOCNO>NCT01704716</DOCNO>
	<brief_summary>This randomise study European SIOP Neuroblastoma Group ( SIOPEN ) high-risk neuroblastoma ( stag 2 , 3 , 4 4 MYCN-amplified neuroblastoma , stage 4 MYCN non amplify &gt; 12 month diagnosis ) . The protocol consist rapid , dose intensive induction chemotherapy ( R3 randomisation - Rapid COJEC v modify N7 ) , peripheral blood stem cell harvest , attempt complete excision primary tumour , myeloablative therapy ( BuMel ) follow peripheral blood stem cell rescue , radiotherapy site primary tumour immunotherapy ( R4 randomisation - isotretinoin ch14.18/CHO , without aldesleukin ( IL-2 ) . In induction phase , patient stage 4 neuroblastoma stage 4 MYCN-amplified neuroblastoma randomise ( R3 ) Rapid COJEC modify N7 ; localise patient receive Rapid COJEC ( Rapid COJEC give G-CSF support base result R0 randomisation run 2002 2005 ) . Following induction treatment peripheral blood stem cell harvest ( PBSCH ) perform complete excision primary tumour attempt . Patients inadequate metastatic response allow BuMel MAT follow PBSCR end induction receive 2 TVD ( Topotecan , Vincristine , Doxorubicin ) cycle . After Rapid COJEC induction , localise patient proceed consolidation . Patients age 12-18 month diagnosis , stage 4 neuroblastoma , MYCN amplification without segmental chromosomal alteration ( SCA ) think good prognosis stop treatment induction therapy surgery primary tumour . Consolidation consist BuMel MAT ( follow result R1 randomisation ) follow peripheral blood stem cell rescue ( PBSCR ) radiotherapy site primary tumour . During immunotherapy phase , patient randomise ( R4 ) immunotherapy isotretinoin ( 13-cis-RA ) ch14.18/CHO , without aldesleukin ( IL-2 ) .</brief_summary>
	<brief_title>High Risk Neuroblastoma Study 1.7 SIOP-Europe ( SIOPEN )</brief_title>
	<detailed_description>In protocol term high-risk neuroblastoma refers child either - disseminated disease ( INSS stage 4 : 40 50 % neuroblastoma ) age one - INSS stage 2 3 disease amplification MycN proto-oncogene Between 10 % 20 % child stage 3 occasional patient stage 2 disease characterise amplification MycN gene tumour . This biological characteristic clearly show associate great risk relapse death disease progression . These patient may benefit aggressive treatment , base hypothesis , include protocol . - Infants ( &lt; 12 month diagnosis ) MYCN amplify tumour include . Children type presentation age represent large neuroblastoma subgroup . Their prognosis remain poor case ability predict clinical course outcome individual patient modest . Primary objective : R0 randomisation : R0 open study activation February 2002 close November 2005 . The randomised use G-CSF COJEC induction result recommendation prophylactic use G-CSF prevent episode febrile neutropenia R1 randomisation : R1 open study activation February 2002 close 10/2010 follow result show significant superiority myeloablative therapy ( MAT ) busulfan melphalan continuous infusion carboplatin , etoposide melphalan ( CEM ) . BuMel standard MAT . R2 randomisation : R2 activate November 2006 ( 13-cis retinoic acid +/- chimeric ch14.18/CHO antibody ) , modify July 2009 suspend August 2013 . R2 randomisation test hypothesis immunotherapy chimeric 14.18/CHO subcutaneous aldesleukin ( IL-2 , Proleukin® ) , follow MAT autologous stem cell transplantation , addition differentiation therapy 13-cis retinoic acid , improve 3-year EFS patient high-risk neuroblastoma . R3 randomisation : R3 open June 2011 test hypothesis modify N7 induction regimen improve metastatic response rate event free survival ( EFS ) compare Rapid COJEC . R4 randomisation : R4 activate April 2014 . The SIOPEN long term infusion ( LTI ) ch14.18/CHO trial successfully lower toxicity profile prolong infusion time total ch14.18/CHO antibody dose 100mg/m² 10 day continuous infusion relapse /refractory patient . Hence HRNBL1.7/SIOPEN study committee wish implement favourable immunotherapy dose schedule time till induction question R3 answer HRNBL1.7/SIOPEN trial may close . Considering high R2 dropout rate patient unable receive immunotherapy cycle IL-2 s.c. combination treatment arm observe effect current SIOPEN LTI trial , suggest address IL-2sc dose new R4 . Therefore potential synergistic effect sc IL-2 address 50 % original s.c. IL-2 dose . The IL-2sc dose hence reduce 3 x 106 IU IL-2/m2/day s.c. HR-NBL1/SIOPEN R4 amendment instead 6 x 106 IU IL-2/m2/day s.c use SIOPEN LTI trial . In second week IT course s.c.IL-2 give day 2 , 4 , 6 , 8 , 10 parallel ch14.18/CHO ctn infusion first 5 day week 2 schedule SIOPEN LTI trial .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>• Established diagnosis neuroblastoma accord International Neuroblastoma Staging System ( INSS ) . Age 21 year . High risk neuroblastoma define either : 1 . INSS stage 2 , 3 , 4 , 4 MYCN amplification , 2 . INSS stage 4 without MYCN amplification age &gt; 12 month diagnosis Patients receive previous chemotherapy except one cycle etoposide carboplatin ( VP16/Carbo ) . In situation patient receive Rapid COJEC induction first Rapid COJEC cycle may replace first cycle VP16/Carbo ( etoposide / carboplatin ) . Written informed consent , include agreement parent legal guardian minor , enter randomise study criterion randomisation meet . Tumour cell material available determination biological prognostic factor . Females childbearing potential must negative pregnancy test . Patients childbearing potential must agree use effective birth control method . Female patient lactate must agree stop breastfeeding . Registration eligibility criterion data centre within 6 week diagnosis . Provisional follow 5 year . National local ethical committee approval . Any negative answer concern inclusion criterion study</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>neuroblastoma</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>MAT</keyword>
	<keyword>antibody treatment</keyword>
</DOC>